Researchers monitored 377 HIV-positive babies for five years and found that those who completed the immediate 96-week antiretroviral treatment were able to avoid restarting the therapy for an average of 70 weeks. Waiting for symptoms to emerge before getting the treatment was linked to substantially higher rates of deaths and hospital admissions as well as greater medical costs than the immediate, temporary treatment. The findings appear in The Lancet.
Early short-term antiretroviral treatment may benefit HIV-positive babies
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|